2016_Head & Neck COURSE BOOK

Anti-EGFR monoclonal antibodies after platinum

Pooled of three prospective phase II trials with cetuximab monotherapy or with platin (N=278)

5.2 - 6.1 months

Retrospective study of patients who received various second-line treatments (N=194)

3.4 – 3.6 months

FDA approval

Vermorken et al. Cancer 2008